{"id":"W4412592901","doi":"10.1177/13524585251355842","title":"Brain atrophy and associations with long-term disability and cognitive function in participants with relapsing multiple sclerosis treated with ozanimod: Results from phase 3 and open-label extension trials","year":2025,"lang":"en","type":"article","venue":"Multiple Sclerosis Journal","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; NeuroRx Research (Canada)","funders":"Janssen Pharmaceuticals; EMD Serono; MedDay Pharmaceuticals; Innosuisse - Schweizerische Agentur für Innovationsförderung; Kiniksa Pharmaceuticals; Shionogi; Genentech; National Multiple Sclerosis Society; Horizon Therapeutics; Celltrion; Atara Biotherapeutics; National Institutes of Health; Mylan; TG Therapeutics; European Committee for Treatment and Research in Multiple Sclerosis; Sanofi; Multiple Sclerosis International Federation; University of Pennsylvania; Alexion Pharmaceuticals; Neuraxpharm; Teva Pharmaceutical Industries; Bayer HealthCare; European Commission; Celgene; Biogen; GlaxoSmithKline; AstraZeneca; Eli Lilly and Company; Samsung; Bristol-Myers Squibb","keywords":"Medicine; Atrophy; Multiple sclerosis; Physical therapy; Internal medicine; Psychiatry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002979571,0.0005650297,0.001610794,0.0003520069,0.001093469,0.0006540552,0.0001435638,0.0002083959,0.00001818597],"category_scores_gemma":[0.008359599,0.0003729374,0.00006287845,0.0008297456,0.0009572791,0.000872737,0.0002894013,0.0008809158,0.000001156736],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003338524,"about_ca_system_score_gemma":0.0002139616,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001682479,"about_ca_topic_score_gemma":0.007244624,"domain_scores_codex":[0.9949007,0.00113994,0.001237455,0.00115967,0.0007437107,0.000818506],"domain_scores_gemma":[0.9922315,0.005388827,0.0007097168,0.000404757,0.0006860183,0.000579107],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.04939333,0.002023014,0.8431696,0.00005964353,0.001164575,0.00003774015,0.0009662607,0.00001565767,0.05335628,9.645022e-7,0.0001208899,0.04969205],"study_design_scores_gemma":[0.1311909,0.003004198,0.8526686,0.005913828,0.001106781,0.0000204777,0.001101499,0.002837514,0.001782593,0.00001126906,0.000006606161,0.0003556934],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9919748,0.001379667,0.00105643,0.001938043,0.00006064675,0.002658147,0.0008440871,0.00005786621,0.00003032888],"genre_scores_gemma":[0.9953093,0.001516924,0.002333018,0.0002315157,0.0001110053,0.0001804637,0.0002148,0.00005908264,0.00004388791],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08179754,"threshold_uncertainty_score":0.9999934,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2598316333941632,"score_gpt":0.3896488495859778,"score_spread":0.1298172161918146,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}